Posttraumatic stress disorder (PTSD) is a chronic anxiety disorder that follows exposure to extreme events. A large twin study of Vietnam veterans had demonstrated a significant genetic contribution to chronic PTSD upon exposure to combat.
Post-traumatic stress disorder (PTSD) is an extreme and sustained maladaptive response to stressful events. The disorder consists of symptoms of intrusive recall, avoidance of cues reminding of the traumatic event and hyper-arousal. These symptoms may persist for years, and are often associated with significant disability and distress. The etiology of PTSD is complex and multifactorial. 3 Importantly, exposure to a traumatic event does not fully explain the occurrence of the disorder. 4 Exposure, in fact, triggers a cascade of biological events that ultimately lead to the occurrence of chronic PTSD. 5 Individuals with prior vulnerability are at higher risk for developing PTSD upon exposure to a traumatic event. Inherited vulnerability is among the better researched vulnerability factors, as follows:
True et al, 1 studied 4042 twin pairs from the Vietnam Twin Registry and found that inherited factors accounted for up to 32% of the variance of PTSD symptoms, above and beyond the contribution of trauma intensity. Xiang et al, 2 examined 3304 twin pairs of the Vietnam Twin Registry and similarly found 35.3%, inherited liability to develop PTSD upon combat exposure, 20% of which pertained specifically to PTSD and an additional 15.3% were common to both PTSD and substance dependence. Other studies 6 have shown an aggregation of anxiety disorders in families of PTSD patients.
The molecular basis of the above-mentioned vulnerability is hardly known at this point. Two association studies evaluated the Taq-I RFLP site near the D2 dopamine receptor (DRD2) gene in PTSD. The first study 7 compared 37 drug and alcohol addicts with PTSD with 19 addicts without PTSD and found higher frequency of the A1 allele among the former. The second study 8 failed to replicate this finding in a sample of 52 PTSD patients and 82 normal controls.
Beyond their conflicting results, these studies are limited by their small sample sizes, by the salient presence of co-morbid substance abuse and by fact that the occurrence of a traumatic event was not evaluated among control subjects of the second and larger study. In such case, some control subjects may have undergone a traumatic event whereas others have not been exposed to a trauma. Importantly, those not exposed could not have expressed the clinical phenotype of PTSD, despite a possible underlying vulnerability. PTSD, in fact, required a triggering trauma in order to be expressed. Thus, the control group could have included both genetically vulnerable and non-vulnerable individuals. Yet, the rationale for implying dopaminergic neurotransmission in the etiology of PTSD is sound. Several human studies have shown increased urinary excretion of dopamine (DA) in PTSD. [9] [10] [11] [12] Urinary excretion of DA correlated with the severity of PTSD symptoms. Higher levels of plasma dopamine were also found in PTSD. 13 In animal studies, dopaminergic innervation of the basolateral nucleus of the amygdala, the medial prefrontal cortex, and other limbic regions is highly responsive to stress and may be altered by stress. 14, 15 Additionally, genetically determined strain-dependent alterations in DA release and DA receptor expression in relevant brain regions of C57 and DBA mice strains have been implicated in differential strain-specific behavioral abnormalities induced by chronic stress. 16 This finding was interpreted as suggesting that stress-induced alterations of central dopa-minergic neurotransmission may be genotype-dependent and expressed in behavior. 17 Finally, exposure to stress augments the locomotor responses to cocaine challenge, partly through altering DA release. Such sensitization was seen as relevant to the pathogenesis of PTSD. 18 The dopamine transporter (DAT) is located pre-synaptically on dopaminergic neurons. Reuptake of dopamine released into the synaptic cleft limits the extent and duration of dopamine receptor activation. A polymorphic VNTR region has been described in the SLC6A3 3Ј untranslated region cDNA sequence, 19 and has been previously associated with several behavioral phenotypes including attention deficit, hyperactivity disorder 20 and tobacco addiction. 21 Functional relevance for the SLC6A3 for in vivo DAT availability has been reported, based on striatal [I-123] ␤-CIT binding, taken to reflect DAT binding availability based on displacement studies of dopamine and serotonin transporter inhibitors. 22, 23 A single positron emission tomography (SPECT) study reported reduced [I-123] ␤-CIT striatal binding in 10 repeat homozygotes compared with 9 repeat carriers in normals, 22 whereas another study reported reduced [I-123] ␤-CIT putamen binding in 9 repeat-10 repeat heterozygotes compared with 10 repeat homozygotes in a mixed sample of normals and abstinent alcoholics. 23 Although unassociated with amino acid substitution, the 3Ј VNTR site may affect DAT expression through mRNA transcription and stability, or through linkage disequilibrium with another functional site.
Given this rationale we investigated DAT gene polymorphism in PTSD and trauma-exposed healthy subjects. We compared a group of 102 patients with chronic PTSD (PTSD group) with 104 trauma survivors who did not develop PTSD (TS control group). The TS group consisted of survivors seen in previous prospective studies of PTSD, 24 whose exposure to traumatic events and whose initial responses to those events had been comprehensively documented, as well as the fact that none of them developed PTSD. Traumatic events among controls included road traffic accidents (75%), war events and terrorist acts (18%) and other traumatic events, such as work accidents, street-and domestic violence (7%). Traumatic events among PTSD patients included road traffic accidents (69%), terrorist acts (25%) and other events (6%). The difference between the groups in not significant statistically.
As shown in Table 1 , there was a significant excess of 9 repeat alleles in chronic PTSD patients (43% vs 30.5% in non-PTSD; 2 = 6.3, df = 1, P = 0.012). The 9 repeat allele was associated with increased risk for PTSD (OR = 1.72, 95% CI = 1.12-2.62). Genotype distribution among the two groups was also significantly different ( 2 = 6.11, df = 2, P = 0.047). There was an excess of 9 repeat homozygotes among the chronic PTSD patients (20.43%) compared to TS (9.47%). Compared to the other genotypes, homozygosity for the 9 repeat allele was associated with an increased risk for chronic PTSD (OR = 2.45, 95% CI = 0.98-6.52).
A linkage disequilibrium (LD) model for phase unknown data 25 also supported association/LD between the DAT VNTR site and PTSD ( 2 = 6.34, df = 2, P = 0.011). SLC6A3 allele distribution was in accordance with Hardy-Weinberg equilibrium (P Ͼ 0.1) in both PTSD and TS groups.
Breakdown of the non-Ashkenazi group into respective countries of origin including North Afrika, Yemen, Iraq, Iran, and other Asian, showed the following results: North Africa (n = 44; 22 with PTSD), Yemen (n = 8; three with PTSD), Iran (n = 8; five with PTSD), Iraq (n = 11; eight with PTSD) and other Asian (n = 11; nine with PTSD; 2 (4,80) = 7.68, P = 0.11). Additionally there was no statistically significant difference in genotype distribution (99, 910, 1010) between the above mentioned non-Ashkenazi ethnic groups ( 2 (8,71) = 13.2, P = 0.11), nor a statistically significant difference in allele (9, 10) distribution ( 2 (4,79) = 5.4, P = 0.25). Logistic regression analysis was applied to evaluate the effect of population origin and diagnosis (ie PTSD or non PTSD) as predictors of the DAT alleles and genotypes frequency; the likelihood ratio (LR) test of the two models (model 1: population + diagnosis and model 2: population alone) determines the significance of diagnosis, controlled for the potential confounding effect of population. The LR test for DAT alleles shows a significant association between DAT and PTSD after controlling for the confounding effect of population stratification ( 2 = 6.42, df 1, P = 0.011), and remains significant when restricting the analysis to the larger Non-Ashkenazi group only ( 2 = 3.93, df = 1, P = 0.0475). The LR test for association between DAT genotypes and PTSD controlling for population, shows again a positive association of DAT with PTSD ( 2 = 6.43, df = 2, P = 0.04). Both analyses confirm that the increased risk to develop PTSD is associated with the DAT locus and cannot be attributed to population based genetic biases.
Fourteen (13.5%) of 104 TS subjects and ten (9.8%) out of 102 PTSD subjects suffered from anxiety disorders ( 2 (4,213) = 1.25, P = 0.87). Eighteen (17.3%) of 104 non PTSD subjects and 62 (60.8%) out of 102 PTSD subjects suffered from depressive disorders ( 2 (4,213) = 43.1, P Ͻ 0.0001). The distribution of DAT genotypes between PTSD subjects with (n = 38) and without (n = 55) depression was statistically similar ( 2 = 0. 2 (df) P 6.31 (1) P = 0.012 6.1 (2) P = 0.047 the SLC6A3 9 repeat allele and 9 repeat homozygous genotype and susceptibility for chronic PTSD. The above-mentioned twin studies, 1,2 suggest a polygenic contribution to susceptibility to develop PTSD among twins exposed to combat. In accordance with this model, our findings indicate that the 9 repeat allele and genotype may contribute to such vulnerability.
The lifetime prevalence of PTSD in the general population is estimated to be of 10%, and the incidence of new cases of PTSD among survivors of traumatic events varies between 2% and 49%. 26 This suggests that among samples not selected for trauma exposure, some proportion of subjects may carry a genetic vulnerability for PTSD, which remains unexpressed for lack of exposure. Assuming multifactorial polygenic inheritance for PTSD, 1 common allelic variation which may possess a small pathogenic effect given a context of adequate trauma exposure, would be expected to be found in different frequencies among differentially selected samples. A frequency gradation should be observed with highest pathogenic allele frequency expected among susceptible samples, intermediate frequency among subjects not selected for trauma exposure (ie 'reference population controls', a proportion of whom may be expected to carry unexpressed genetic vulnerability for PTSD), and lowest frequency among a less susceptible sample of trauma survivors not expressing PTSD. Alternatively an allele possessing protective effect would be expected to show the reverse gradation. A previous study of SLC6A3 allele frequencies in normal Jewish population non selected for trauma exposure, has shown 15% and 35% for 9 repeat homozygotes and allele carrier frequencies respectively. 27 Compared with our finding, this frequency is indeed between that found for PTSD and that found in trauma-exposed non-PTSD subjects (ie, between 20.4% and 9.5% 9-repeat homozygotes, respectively for PTSD and TS, and between 43% and 30.5% 9 allele carrier frequency for the same groups; see Table 1 ). The group difference (PTSD, Trauma survivors without PTSD, normal Jewish population) is statistically significant ( 2 (df = 2) = 6.5; P Ͻ 0.05) Differences in allele frequencies for the SCL6A3 polymorphic site 28 have been reported among different ethnic populations. Ethnic stratification, however, is unlikely to explain our results, as both our data and the above-mentioned study of non-traumatized Jewish Molecular Psychiatry controls 27 show similar allele frequencies among Ashkenazi and non-Ashkenazi Jews. Moreover, our study groups had a similar ethnic distribution. Independent replication, preferably through transmission disequilibrium design is required to confirm our results. Such design would be immune to both ethnic confounds and false-negative diagnoses which may occur in casecontrol studies of trauma survivors.
These results provide direct evidence for the involvement of SLC6A3 allelic status in the etiology of PTSD. If replicated, they imply that variations in dopaminergic neurotransmission may mediate the pathological response to trauma, and, in general, the vulnerability to the effect of stress. They also suggest that trauma-exposure should be monitored in case control studies of PTSD.
Materials and methods

Subjects
All subject candidates for this study signed a written informed consent, as sanctioned by the Human Use Committee of Hadassah University Hospital. Subjects were considered for inclusion in this study if they were between 18 and 65 years old, had experienced an event meeting DSM-IV PTSD criterion A (an operational definition of a traumatic event) and were Jewish of definite Ashkenazi or non-Ashkenazi origin (both parents being of Ashkenazi or non-Ashkenazi origin). Subjects were not included in this study if they suffered from head injury, burn injury or serious physical injury. Additionally, subjects with current or lifetime use of alcohol or illicit drugs, those with past or present psychosis, and those suffering from medical or neurological illness that could confound the assessments, were not included.
PTSD subjects (n = 102) were recruited among participants of follow-up studies of this disorder 24 and among subjects presenting for treatment in outpatient clinics in Jerusalem. All PTSD subjects met DSM-IV diagnostic criteria for current PTSD as obtained by the Clinician Administered PTSD Scale (CAPS) 29 -a structured clinical interview for PTSD. The co-occurrence of other mental disorders was ascertained by the Structured Clinical Interview for DSM-IV Mental Disorders (SCID). 30 Both instruments had been extensively used in previous studies of PTSD and other mental disorders and were administered by clinicians with extensive experience in research, diagnosis and treatment of PTSD (RK, RS).
Control subjects (n = 104) were equally recruited among participants of prospective longitudinal studies of PTSD. 24 Participants in these studies were followed, for up to 6 months, from the time of their admission to an emergency room, following a traumatic event. Information regarding the traumatic event and the early psychological responses was obtained within 10 days of admission to the emergency room. The presence of PTSD was detected, via clinical interviews using the CAPS, at 1 and 4 months following trauma. Control subjects did not have PTSD at both 1 and 4 months.
The study groups had similar gender distribution (55.8% vs 47.1% males among PTSD and non-PTSD respectively; 2 = 1.58, df = 1, P Ͼ 0.20). The mean age at the time of the traumatic event was somewhat higher among PTSD subjects (39.7 ± 11.7 vs 33.9 ± 10.2 years, P Ͻ 0.05). Lifetime history of mental disorders was higher among PTSD subjects (12.6% vs 1.1% in TS; 2 = 9.07, df = 1, P Ͻ 0.005).
The study groups were of similar ethnic origins (Ashkenazi 37.6% vs 39.7%, among PTSD and non-PTSD respectively; P Ͼ 0.1). Further breakdown of the non-Ashkenazi group into respective countries of origin including North Africa, Yemen, Iraq, Iran, and other Asian, showed no significant differences between PTSD and controls ( 2 (df = 4,80) = 7.6; P = 0.11), and there was no significant difference in DAT allele ( 2 (df = 4,79) = 5.4; P = 0.25) or genotype ( 2 (df = 8,71) = 13.2; P = 0.11) distribution among subjects from the different countries of origin within the two groups.
Genotyping
Genotyping of the SCL6A3 DAT 3Ј VNTR polymorphism was performed by PCR based restriction analysis, as previously described. 19 
Statistical analyses
The Stata-6 program and Statistica for Windows were used for statistical analyses. There were no differences in allele frequency for the SCL6A3 alleles between subjects of Ashkenazi and non-Ashkenazi origin among the control and patient groups; therefore, the groups were combined for statistical analysis. Maximum likelihood chi-square statistics were used for categorical analyses. Differences between groups on continuous variables were evaluated by t-test. Significance levels are for two-tailed tests; P values Ͻ0.05 (twotailed) were regarded as significant.
A linkage disequilibrium (LD) model for phase unknown data was employed as previously described by Mander & Clayton (2000) . 25 This method calculates allele/haplotype frequencies using log-linear modeling embedded within an EM algorithm. The EM algorithm handles the phase uncertainty and the log-linear modeling allows testing for linkage disequilibrium and disease association. The log-linear model is fitted using iterative proportional fitting which is implemented in a specific routine of the Stata 6.0 program which can handle very large contingency tables and converges to maximum likelihood estimates. The data to be entered consist of paired variables representing the alleles at each locus. If phase is known then the pairs are the genotypes. When phase is unknown the algorithm assumes Hardy-Weinberg equilibrium so that models are based on chromosomal data and not genotypic data.
To evaluate the relationship of more than one independent variable to DAT alleles and/or genotypes, a logistic regression procedure was implemented. The outcome variable of the logistic regression was the presence of the DAT alleles or genotypes, employing a multinomial logistic regression test. The covariates of the model were the clinical phenotype of interest (ie presence/absence of PTSD) and the ethnicity, given a possible population effect on the frequency of DAT alleles and genotypes. In this case, the phenotype of interest is regarded as a predictor of the outcome, and ethnicity as a potential confounder. To increase the resolution for detecting a possible ethnic stratification effect, in addition to the traditional dichotomous division of subjects to 'Ashkenazi' or 'Non Ashkenazi' groups, we further evaluated their specific country of birth, as well as their father's and mother's country of birth. Results from the model are presented as Likelihood Ratio Tests. P values of Ͻ0.05 (two-tailed) were regarded as significant in all analyses. With this approach, we checked for the homogeneity of the Odds Ratios (OR) across possible population differences and tested whether the observed association between DAT (alleles and genotypes) and PTSD is due to a 'true' association or is an effect of a population-specific variability. This method has been previously successfully applied in other studies where there was the need to assess for a potential effect of population variability. 31 Hardy-Weinberg equilibrium (P Ͼ 0.1) in both PTSD and TS groups was calculated with the utility program of J Ott (http://linkage.rockefeller.edu/ott/linkutil. htm).
